Researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have provided solid evidence that copper, the first metal used medicinally, may now have a new role — helping save children from a devastating central nervous system cancer known as medulloblastoma.
In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
No parent wants to hear the word “cancer.” Fortunately, few will, but it’s always smart to be attuned to signs that might warrant a further look. Two Penn State Health Children’s Hospital doctors discuss the warning signs.
Results from a large phase 3 noninferiority clinical trial definitively showed that vincristine and dexamethasone pulses can be eliminated in patients with low-risk disease. The findings were published today in The Lancet Oncology.
Known as HIPEC, the therapy has been available for adults for years at Michigan Medicine. Now it’s an option for kids here, too.
St. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
St. Jude Children’s Research Hospital scientists have shown that frailty contributes to neurocognitive decline in young adult survivors of childhood cancer.
St. Jude Children’s Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment.
#TeamTKC Captain Eli Manning Helps Launch Inaugural Virtual 5K to Tackle Kids Cancer
A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.
Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital
Scientists at St. Jude Children’s Research Hospital are learning more about what the molecular groups of a rare pediatric brain tumor mean for clinical care.
In the spirit of growing scientific collaboration, grants will provide support for four projects across 15 research institutions using cutting-edge technology to address crucial issues in pediatric cancer research
Childhood cancer and its treatment can result in cognitive struggles. St. Jude scientists are studying the risk factors.
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
Research from scientists at St. Jude Children’s Research Hospital found mutations up to two years before cancer developed, showing an opportunity for early interventions.
A pair of research papers from St. Jude Children’s Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
In a large study of pediatric cancer patients, researchers from Children’s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.
Philanthropic initiative of the Children’s Cancer Institute, reaches five year milestone combatting pediatric cancer
Recent research from Rutgers Cancer Institute of New Jersey expert as part of a phase 3 study from the Children’s Oncology Group explores response-based consolidation with modern radiation therapy as safe and effective standard of care for pediatric Hodgkin lymphoma patients. This work is being presented at the Annual Meeting of the American Society for Radiation Oncology (ASTRO) this week.
Researchers have demonstrated that a new liquid biopsy approach overcomes traditional barriers to quickly and efficiently diagnose and monitor high-grade pediatric gliomas.
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
The University of Chicago Pediatric Cancer Data Commons and The Leukemia and Lymphoma Society are working together to bring precision medicine to children and young adults with acute leukemia.
Family looks to the ‘bright side’ by creating a charity to support pediatric cancer research and providing UChicago Medicine Comer Children’s Hospital with $500,000 gift.
In a breakthrough study, researchers at Children’s Hospital of Philadelphia (CHOP) have shown that an enhanced treatment developed in their lab leads to long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The research, which could soon lead to clinical trials, is described in Cancer Research, a journal of the American Association for Cancer Research.
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Foundation receives generous donation from corporate partner to combat pediatric cancer and benefit patient care
St. Jude Children’s Research Hospital develops the Childhood Solid Tumor Network data portal to speed discoveries and novel therapies for treatment of childhood solid tumors
The American Association for Cancer Research honored St. Jude President and CEO James R. Downing, M.D., with its inaugural AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research.
Children’s Hospital Los Angeles (CHLA) ranks again among the nation’s premier destinations for pediatric care, according to the U.S. News & World Report Best Children’s Hospitals annual list released today. Hospital retains national No. 5 ranking and is highest scoring children’s hospital in Western United States.
Researches from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) found that children with cancer are not at a higher risk of being affected by COVID-19.
Article title: Angiotensin-(1–7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms Authors: Omeed Rahimi, Jay Kirby, Jasmina Varagic, Brian Westwood, E. Ann Tallant, Patricia E. Gallagher From the authors: “[Angiotensin]-(1–7) is a clinically safe peptide hormone with cardioprotective…
Collaboration co-led by researchers at St. Jude Children’s Research Hospital discovers a novel predisposition gene in pediatric medulloblastoma.
Scientists at St. Jude Children’s Research Hospital have identified a novel target for a type of pediatric brain tumor.
Of 1,881 patients under age 19 diagnosed with cancers of the brain and central nervous system between 2000 and 2015, 52 percent of White patients lived five years from diagnosis, whereas only 44 percent of African American patients and 45 percent of Hispanic patients reached a similar milestone.
St. Jude Children’s Research Hospital pediatrician and researcher is honored for significant contributions to the advancement and impact of global collective efforts to save more lives from childhood cancer.
In experiments with human cells and mice, researchers at the Johns Hopkins Kimmel Cancer Center report evidence that combining the experimental cancer medication TAK228 (also called sapanisertib) with an existing anti-cancer drug called trametinib may be more effective than either drug alone in decreasing the growth of pediatric low-grade gliomas. These cancers are the most common childhood brain cancer, accounting for up to one-third of all cases. Low grade pediatric gliomas arise in brain cells (glia) that support and nourish neurons, and current standard chemotherapies with decades-old drugs, while generally effective in lengthening life, often carry side effects or are not tolerated. Approximately 50% of children treated with traditional therapy have their tumors regrow, underscoring the need for better, targeted treatments.
The Together website by St. Jude offers information about diseases, diagnosis and treatment options, as well as supportive care resources and shared stories of hope, healing and experience.
Along with a healthy lifestyle, regular screening can help with the prevention of cancer. Rutgers Cancer Institute of New Jersey experts share additional information during this Cancer Prevention Month.
Ten years ago this week St. Jude Children’s Research Hospital and Washington University School of Medicine unveiled an ambitious collaboration to identify the genetic changes that lead to some of the world’s deadliest childhood cancers. The researchers proposed a three-year, $65 million project to sequence the complete normal and cancer genomes of more than 600 childhood cancer patients.
Researchers from St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated. The findings were reported today in JAMA Oncology.
A $150,000 pledge from the Om Foundation will aid investigators at Rutgers Cancer Institute of New Jersey in examining a certain type of medication that impacts gene activity in the treatment of a form of pediatric brain cancer.
A St. Jude Children’s Research Hospital study lowered the rate of relapse for patients with acute lymphoblastic leukemia.
HMS scientist’s work will aim to elucidate the role of cellular decision-making in cancer development
The International Atomic Energy Agency (IAEA) and St. Jude Children’s Research Hospital are joining forces to combat childhood cancers in developing countries.
Firearm injuries kill 2,500 American children each year. But the nation spends far less on studying what led to these injuries, and what might prevent and treat them, than it spends on other causes of death in children. In fact, on a per-death basis, funding for pediatric firearm research is 30 times lower than it would have to be to keep pace with research on other child health threats.
Roswell Park’s Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.
With the aim of improving pain control and decreasing hospitalizations for vaso-occlusive crisis, the Sickle Cell Team at Children’s of Alabama is moving to implement individualized pain plans for patients and pilot an outpatient pain clinic.